Background/Aims: Recent studies have revealed that many long non-coding RNAs (lncRNAs) play oncogenic or tumor-suppressive roles in various cancers. Lung cancer is the leading cause of cancer-related death worldwide, and many lung cancer patients frequently relapse after surgery, even those in the early stages. However, the oncogenic or tumor-suppressive roles and clinical implications of lncRNAs in lung cancer have not been fully elucidated.
5 lung cancer cells were plated in 6-well plates and incubated overnight. The siRNAs or non-targeting controls at a concentration of 50 nM were transfected into lung cancer cells using Lipofectamine 2000 in Opti-MEM media. After 4 hours of incubation, the media were changed to complete media, and 48 hours after transfection, gene knockdown was confirmed by RT-qPCR.
Reverse transcription qPCR
Total RNA was extracted using the RNeasy Mini Kit (QIAGEN) according to the manufacturer's instructions. Reverse transcription was performed with 1 μg of total RNA as the template and M-MLV Reverse Transcriptase (Promega). Quantitative realtime PCR (qPCR) reactions were performed in triplicate on a LightCycler 480 machine (Roche) using LightCycler 480 SYBR Green I Master Mix (Roche). cDNA expression was normalized to that of β-actin, and at least three independent biological replicates were included for each reaction. The primers used for qPCR were designed either manually or with the Primer3 program (http://biotools.umassmed.edu/bioapps/primer3_www.cgi). All primer sequences are listed (see suppl. material) in Suppl. Table 2 .
Proliferation assay
Suspensions of 1.0 to 2.0 x 10 3 cells were seeded into 96-well plates. After 48 to 72 hours of incubation at 37°C, a CyQUANT NF Cell Proliferation dye reagent and deliverer (Invitrogen) mixture was added. After 30 min of incubation, the fluorescence intensity ratio of 530 nm to 485 nm was measured.
Invasion assay
Transwell chambers (Corning) were coated with Matrigel Basement Membrane Matrix (BD). Cells were suspended in serum-free media and seeded into the upper chamber at a density of 2.0 to 5.0 x 10 4 cells per well, and serum-containing media were placed into the lower chamber. After incubation for 24 ~ 72 hours, cells penetrating the pores were stained with Diff-Quik staining solution (Sysmex) and observed under a microscope.
Microarray analysis
In total, 750 ng of each cRNA library was prepared from the total RNA samples, hybridized to the HumanHT-12 Gene Expression BeadChip (Illumina), and measured according to the manufacturer's instructions. The intensity values were analyzed with the GenomeStudio program and globally normalized using the quantile method. Gene set and pathway analyses of differentially expressed genes were performed using the Gene Set Enrichment Analysis (GSEA) program (http://software.broadinstitute.org/gsea/index. jsp).
RNA immunoprecipitation assay Table 3 . RIP-qPCR amplifications were performed in triplicate on the LightCycler 480 machine using LightCycler 480 SYBR Green I Master Mix. Data were normalized to the input levels, and at least three independent biological replicates were included for each RIP-qPCR. The primer sequences are listed (see suppl. material) in Suppl. Table 2 .
Nucleus/cytoplasm fractionation Nuclear and cytosolic fractions were separated using the PARIS kit (Ambion) according to the manufacturer's instructions
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) was performed using Dynabeads Protein A and G (Thermo Fisher Scientific). First, 5.0 x 10 6 cells were cross-linked with 1% formaldehyde for 10 min at 25°C. Then, the cells were lysed and sonicated using the truChIP Chromatin Shearing Reagent Kit (Covaris) according to the manufacturer's instructions. The expected fragment size was between approximately 200 and 500 base pairs. Samples were diluted five-fold with low-salt RIPA buffer (0.1% SDS, 1% Triton X-100, 1 mM EDTA, 140 mM NaCl, 4% deoxycholate) and pre-cleared with 50 µl of Dynabeads Protein A and G for 1 hour at 4°C. Primary antibodies were added to pre-cleared supernatants, and the mixtures were incubated overnight at 4°C. The antibodies used for the ChIP assay are listed (see suppl. material) in Suppl. Table 3 . Next, 50 µl of Dynabeads Protein A and G were added to the samples, and the mixtures were incubated for 2 hours at 4°C. The beads were subsequently washed with wash buffer (low-salt RIPA, high-salt RIPA, LiCl, and TE). After 15 min of incubation at 65°C, precipitated chromatin was eluted twice in 250 µl of elution buffer (0.1 M NaHCO 3 and 1% SDS). Reverse cross-linking was performed for 4 hours at 65°C, and chromatin was then treated with RNase A for 1 hour at 37°C and proteinase K for 1 hour at 45°C. DNA was purified with phenol/ chloroform extraction or a QIAquick PCR Purification Kit (QIAGEN).
ChIP-qPCR reactions were performed in triplicate on the LightCycler 480 machine using LightCycler 480 SYBR Green I Master Mix. The data were normalized to the input levels, and at least three independent biological replicates were included for each ChIP-qPCR. The primer sequences are listed (see suppl. material) in Supp. Table 2 .
Data availability
Microarray data have been deposited in the GEO database under accession number GSE102356.
Results

Promotion of lung cancer progression by EPEL
The human chromosome 4 (NCBI37/hg19) genomic locus from 183, 059, 813 to 183, 065, 668 is annotated as LOC90768 or MGC45800 and encodes a not yet characterized lncRNA that we named EPEL. According to Encyclopedia of DNA Elements (ENCODE) data, the locus is occupied by active histone markers, and EPEL is transcribed in various cell lines (GM12878, H1-hESC, HeLa-S3, HepG2, HSMM, HUVEC, K562, NHEK, NHLF cell lines) (see suppl. material, Suppl. Fig. 1 ). EPEL expression was higher in tumor lung tissues (lung-C) than in normal lung tissues (lung-N) according to the Gene Expression across Normal and Tumor tissue (GENT) database (see suppl. material, Suppl. Fig. 2 ) [51] . We analyzed two public gene expression datasets (GSE31210 and GSE50081) to evaluate the clinical significance of EPEL in lung cancer patients [52, 53] . We first compared EPEL expression between non-relapsed (or non-recurrent) and relapsed (or recurrent) patients and found that EPEL was up-regulated among lung cancer patients with relapse or recurrence (Fig.  1a) . Increased EPEL expression was associated with poor survival after surgery (Fig. 1b) . By analyzing additional public datasets, we found that increased EPEL expression was also associated with the poor survival of other cancer patients, including breast cancer, Ewing's sarcoma and melanoma (see suppl. material, Suppl. (Table 1) , we found that only EPEL expression and histological staging could predict poor survival in both datasets. Thus, we suggest that EPEL expression is a good prognostic marker for lung cancer.
Promotion of lung cancer cell proliferation and invasion by EPEL
As the level of EPEL expression was associated with lung cancer progression, we examined which cancer-related phenotypes were influenced by EPEL expression in lung cancer cells. Using siRNAs for EPEL, we knocked down EPEL in A549 and NCI-H1299 lung cancer cell lines. We first validated that EPEL was successfully knocked down by three siRNAs in both A549 and NCI-H1299 lung cancer cells using the RT-qPCR assay ( Fig. 2a ) and then performed cell proliferation assays. EPEL knockdown significantly decreased the proliferation of A549 and NCI-H1299 cells (A549: 62% decrease for siEPEL #1, 26% decrease for siEPEL #2, 31% decrease for siEPEL #3; NCI-H1299: 31% decrease for siEPEL #1, 41% decrease for siEPEL #2, 46% decrease for siEPEL #3). We next performed an invasion assay with cells transfected with treatment siRNAs and a control siRNA. EPEL knockdown significantly decreased the invasion of A549 and NCI-H1299 cells ( Fig. 2c ) (A549: 65% decrease for siEPEL #1, 59% decrease for siEPEL #2, 52% decrease for siEPEL #3; NCI-H1299: 53% decrease for siEPEL #1, 44% decrease for siEPEL #2, 58% decrease for siEPEL #3). Thus, we concluded that EPEL promoted lung cancer proliferation and invasion, which is important for lung cancer 
Regulation of E2F target and cell cycle-related genes by EPEL
To identify genes regulated by EPEL, we performed microarray-based gene expression analysis after treating A549 lung cancer cells with either EPEL or control siRNAs. To identify functional gene categories influenced by EPEL knockdown, we performed GSEA analysis Cellular Physiology and Biochemistry using the microarray data. By GSEA analysis with the Hallmark gene set, we found five gene sets to be significantly down-regulated by EPEL knockdown, including two cell cyclerelated gene sets (G2M_CHECKPOINT and MITOTIC_SPINDLE) and one E2F-related gene set (E2F_TARGETS) (FWER p < 0.01) (Fig. 3a and see suppl. material, Suppl. Table 4 ). Then, we performed GSEA analysis with Transcription Factor Target (TFT) gene sets, and among the top 20 TFT gene sets, the top 18 were E2F target-related (see suppl. material, Suppl. Table 5 ). Moreover, all TFT gene sets significantly down-regulated by EPEL knockdown were also E2F target-related gene sets (FWER p < 0.01) (Fig. 3b) . Thus, the results implied the significance of E2F target regulation by EPEL in lung cancer. E2F promotes various cancer-related functions, such as cell cycle progression and metabolism, while also promoting opposite cancer-related functions, such as apoptosis, according to its binding partners [30, 54] . Roworth et al. reported that each E2F function (cell cycle progression, metabolism, or apoptosis) is associated with its corresponding target genes [30] . When we examined the expression patterns of E2F target genes in our microarray data categorized by cancer-related functions, only cell cycle-related E2F target genes were down-regulated by EPEL knockdown, while metabolism-related and apoptosis-related E2F target genes did not change consistently (Fig. 3c) . Thus, we concluded that EPEL specifically GSEA (TFT) FWER p < 0.01 BRCA1  CCNA2  CCNB1  CDC6  CDK2  E2F1  E2F2  E2F3  FEN1  LIG1  MCM3  MCM6  MLH1  MSH2  PCNA  POLA1  RAD54L  TOP2A  TYMS   APAF1  BAD  BAK1  CASP3  CASP7  TP53  TP73   ARID1B  BRD2  CHD8  E2F1  MDM2  NPDC1  TOPBP1  TRIM28  TRRAP  TSN   COX7C  DRAM1  FH  PDK1  SLC25A10  ULK1  VARS   ABCG2  MMP16  SLC3A2  TRAF2 
Transcriptional regulation of the E2F1 target genes by EPEL
According to GSEA analysis of our microarray data, a set of cell cycle-related E2F1 target genes was the most down-regulated by EPEL knockdown (Fig. 3b and see suppl. material, Suppl. Table 5 ). We hypothesized three possibilities for E2F1 target gene regulation by EPEL: 1) transcriptional regulation of E2F1 by EPEL, 2) post-transcriptional or translational regulation of E2F1, and 3) regulation of E2F1 activity by direct interaction between EPEL and E2F1. The first hypothesis was rejected, as E2F1 expression was not down-regulated in our EPEL knockdown microarray data (Fig. 3c) . For the second hypothesis, we performed an immunoblot assay with an E2F1-specific antibody after EPEL knockdown in A549 lung cancer cells (see suppl. material, Suppl. Fig. 4) . However, because the protein level of E2F1 was not changed significantly by EPEL knockdown, the second hypothesis was also rejected. For the third hypothesis, we first tested direct interaction between EPEL and E2F1 using RIP and qPCR assays with an E2F1-specific antibody and an EPEL-specific primer and found that EPEL directly interacted with the E2F1 transcription factor (p = 1.0 x 10 -4 , t-test) (Fig. 4a) . Because EPEL should be located in the nucleus for direct interaction with the E2F1 transcription factor, we separated the nuclear and cytoplasmic fractions of A549 cells and , t-test). b. Subcellular localization of EPEL, RNA-U1 (nucleus-specific RNA) and GAPDH (cytoplasm-specific RNA). c. ChIP-qPCR assay with an E2F1 antibody on the E2F1 target promoters after EPEL knockdown (p = 0.0021 for CCNB1, p = 0.0023 for FEN1, p = 0.016 for TOP2A, t-test). d. qPCR assay with a pol II CTD (phospho-S5) antibody on the E2F1 target promoters after EPEL knockdown (p = 5.3 x 10-5 for CCNB1, p = 0.0062 for FEN1, p = 0.0012 for TOP2A, t-test). e. RT-qPCR assay for the E2F1 target genes after EPEL knockdown (p = 0.0018 for CCNB1, p = 0.0024 for FEN1, p = 0.0023 for TOP2A, t-test). Data are representative of three independent experiments. The error bars represent the s.e.m. *p<0.05, **p<0.01, ***p<0.001, t-test. performed RT-qPCR assays using primers specific for EPEL, RNA-U1 (nucleus-specific RNA) and GAPDH (cytoplasm-specific RNA) to identify the subcellular localization of EPEL (Fig.  4b) . EPEL was mostly detected in the nuclei of A549 cells, and we thus concluded that EPEL directly interacted with the E2F1 transcription factor in the nucleus.
To examine the target genes of EPEL transcriptional regulation through E2F1 binding, we selected CCNB1 (cyclin B1), FEN1 (Flap endonuclease 1) and TOP2A (DNA topoisomerase 2-alpha) as putative targets [30, 55] (Fig. 3c) . We examined whether EPEL regulated the binding of E2F1 to its target genes. Using ChIP-qPCR with an E2F1 antibody after EPEL knockdown in A549 cells, we found that EPEL knockdown decreased E2F1 occupancy in the E2F1 target promoter regions, including the transcription start site (TSS) (Fig. 4c) . To examine the effect of EPEL knockdown on the TSS transcriptional machinery, we performed ChIP-qPCR with an RNA polymerase II (pol II) carboxy-terminal domain (CTD) phosphoserine 5 (p-S5) antibody after EPEL knockdown in A549 cells. EPEL knockdown decreased the occupancy of the active form of pol II (pol II CTD p-S5) in the promoter regions, including the TSS (Fig. 4d) . Then, we performed an RT-qPCR assay after EPEL knockdown in A549 cells to validate the regulation of the expression of E2F1 target genes by EPEL (Fig. 4e) . Consistent with our microarray data, the expression was down-regulated by EPEL knockdown, and we thus concluded that EPEL affects the proliferation of lung cancer cells by regulating the transcription of E2F1 target genes including CCNB1 through interaction with the E2F1 transcription factor.
Clinical implications of CCNB1 transcriptional regulation by EPEL
Previously, we showed that high EPEL expression levels were significantly associated with the poor prognosis of lung cancer patients (Fig. 1b) . Using the same dataset, we analyzed the clinical relevance of CCNB1 transcriptional regulation by EPEL (Fig. 5a ). CCNB1 -5 for the disease-free survival of GSE50081 (n = 128), log-rank test) (red: high expression group, blue: low expression group). b. Prognosis of lung adenocarcinoma patient groups stratified by EPEL and CCNB1 expression (3.7 x 10 -4 for the overall survival of GSE31210 (n = 204), p = 1.2 x 10 -4 for the relapse-free survival of GSE31210 (n = 204), 5.9 x 10 -4 for the overall survival of GSE50081 (n = 128), p = 3.5 x 10 -4 for the disease-free survival of GSE50081 (n = 128), stratified analysis) (blue: low EPEL, low CCNB1; orange: low EPEL, high CCNB1; purple: high EPEL, low CCNB1; red: high EPEL, high CCNB1). expression was significantly associated with the prognosis of lung adenocarcinoma patients in both datasets ( Fig. 5a ; 3.7 x 10 -4 for the overall survival of GSE31210 (n = 204), p = 1.2 x 10 -4 for the relapse-free survival of GSE31210 (n = 204), 5.9 x 10 -4 for the overall survival of GSE50081 (n = 128), p = 3.5 x 10 -4 for the disease-free survival of GSE50081 (n = 128), log-rank test). We also examined the effect of combined EPEL and CCNB1 expression on the prognosis of lung cancer patients. We divided patients into four groups according to their EPEL and CCNB1 expression levels and performed survival analyses (Fig. 5b) . Patients in the high EPEL and high CCNB1 expression groups exhibited the worst prognosis (3.7 x 10 -4 for the overall survival of GSE31210 (n = 204), p = 1.2 x 10 -4 for the relapse-free survival of GSE31210 (n = 204), 5.9 x 10 -4 for the overall survival of GSE50081 (n = 128), p = 3.5 x 10 -4 for the disease-free survival of GSE50081 (n = 128), stratified analysis), implying that increased CCNB1 expression induced by EPEL may play a critical role in lung cancer progression. We also examined the effect of combined EPEL and other E2F1 target gene expression on the prognosis of lung cancer patients (see suppl. material, Suppl. Fig. 5 ). Thus, we suggest that the transcriptional regulation of CCNB1 by EPEL is an important mechanism for lung cancer progression.
Discussion
While recent high-throughput genomics tools, including microarray and RNA-seq, have allowed researchers to identify thousands of novel disease-associated lncRNAs, detailed functional characterization has been limited to only a small portion of those identified. Here, we report the functional characterization of a new lncRNA, EPEL, as a promising prognostic marker in lung cancer.
We first analyzed several public microarray datasets, identified many novel lung cancerassociated lncRNAs and selected EPEL as a good candidate for subsequent analysis for the following reasons: EPEL was significantly associated with the relapse and survival of lung cancer patients, was transcribed in various cell lines according to ENCODE data, was stabilized by the poly(A) tail and was not genomic DNA contamination, as it was composed of four exons. Then, we characterized EPEL, including analysis of its direct interacting proteins, its subcellular localization, and the transcriptional regulation of its target genes in lung cancer.
E2F1 is a multi-functional transcription factor that interacts with various proteins and is regulated by multiple mechanisms, including the phosphorylation of its binding partner Rb, the SUMOylation of E2F1, and its binding with lncRNAs [22, 26, 27, 30] . Interestingly, several lncRNAs, such as NEAT2, TUG1 and GASL1, were recently identified as E2F1 regulators [22, 56] , and we add EPEL as another lncRNA that directly interacts with E2F1 in lung cancer. As we showed, EPEL interacted with E2F1 and regulated the transcription of E2F1 target genes, including CCNB1 in lung cancer cells. Many lncRNAs are known to be expressed and function in a tissue-specific manner [1, 3, 47, [57] [58] [59] [60] . By surveying previous studies, we found eight lncRNAs that directly interact with E2F1 transcription factors. Among them, four (GASL1 [56] , lncRNA-HIT [61] , GAS5 [62, 63] and ANRIL [64] ), interacted with E2F1 in lung tissues or cells, while the other factors, including Khps1 [58] , ERIC [59] , TUG1 [22] and NEAT2 [22] , had no known functions in lung tissues or cells.
The expression level of EPEL was higher in tumor tissues than normal tissues and was associated with not only the prognosis of lung cancer but also that of other cancer types (tumor-normal difference: skin, bladder, blood, colon, esophagus, ovary, pancreas; prognosis: melanoma, breast cancer, Ewing's sarcoma) (see suppl. material, Suppl. Fig. 2 and 3 ). While we focused on the lung-specific function of EPEL in this study, we expect that EPEL may interact with E2F1 and exert other specific functions in other cancers based on the tissuespecific patterns of EPEL expression in other cancers.
Due to the lack of catalytic activity, lncRNAs play mostly structural roles, including acting [6, 9, 14] . E2F1 has two opposite roles in cancer cell growth: cell cycle control and apoptosis [30] . By changing its lncRNA partners, E2F1 can play opposite roles in cell growth by transcribing different sets of specific target genes. For example, the E2F1-GAS5 interaction inhibits cellular proliferation by targeting P27 Kip1 [63] , while the E2F1-lncRNA-HIT interaction promotes cellular proliferation by targeting Survivin, FOXM1, SKP2, NELL2 and DOK1 [61] . Similar to other lncRNAs, EPEL does not have catalytic activity but fine-tunes the transcriptional regulation of E2F1 by determining the specificity of E2F1 target genes. According to our results, EPEL had specific effects on the expression of cell growth-related E2F1 target genes, including CCNB1, in lung cancer, but not E2F1 target genes related to apoptosis and metabolism, implying that EPEL regulates the specific function of E2F1 by managing the selection of E2F1 target genes. CCNB1 is a key regulator of cell cycle and proliferation, and we demonstrated that EPEL directly regulated CCNB1 transcription by regulating the E2F1 binding efficiency on the promoter. Both EPEL and CCNB1 had potential as prognostic markers for lung cancer by themselves and highly effective at identifying patients with poor prognoses when expressed in combination, implying that the dysregulated transcription of CCNB1 by E2F1 controlled by EPEL is an essential mechanism for lung cancer tumorigenesis and progression.
Conclusion
Considering that the combination of EPEL and E2F1 target gene expression is closely associated with lung cancer prognosis and that EPEL specifically affects the cell cycle-related target genes of E2F, targeting the interplay between EPEL and E2F1 would be a more precise method than targeting E2F1 itself. Thus, we suggest that the interplay between EPEL and E2F1 has translational therapeutic potential.
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